1
|
Wadey C, Rockman S. Analysing the Potency of a Seasonal Influenza Vaccine Using Reference Antisera from Heterologous Strains. Vaccines (Basel) 2024; 12:596. [PMID: 38932325 PMCID: PMC11209104 DOI: 10.3390/vaccines12060596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 05/15/2024] [Accepted: 05/23/2024] [Indexed: 06/28/2024] Open
Abstract
The potency of inactivated seasonal influenza vaccine is harmonised by establishing the haemagglutinin (HA) content using the compendial single radial diffusion (SRD) method. SRD reagents (antigens and antisera) are prepared, calibrated and distributed by regulatory agencies as standards for potency testing, following the biannual World Health Organization (WHO) announcements of the virus strains suitable for inclusion in the vaccine. The generation of a homologous hyperimmune sheep antiserum constrains the time to vaccine release. This study tests the application of heterologous antisera to determine the potency of influenza vaccine compared to that of a standard homologous antiserum. The results indicate that the selected heterologous sheep antisera directed to seasonal H1N1, H3N2 or B Victoria virus strains can be used to determine the accurate potency of inactivated seasonal influenza vaccines. Individually selected antisera could be useful for two to fourteen seasons. A limitation to the heterologous antiserum approach is the diversity of each individual serum, indicating that the empirical determination of a specific serum is required. This application has the potential to enable the earlier availability of a seasonal vaccine and reduce animal usage.
Collapse
Affiliation(s)
| | - Steven Rockman
- CSL Seqirus, Melbourne, VIC 3000, Australia;
- Department of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3010, Australia
| |
Collapse
|
2
|
Hamamoto I. Developments and current challenges in the process of cell culture-based seasonal influenza vaccine manufacture in Japan. Glob Health Med 2024; 6:93-100. [PMID: 38690131 PMCID: PMC11043132 DOI: 10.35772/ghm.2023.01070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 11/25/2023] [Accepted: 12/22/2023] [Indexed: 05/02/2024]
Abstract
Seasonal influenza is an acute respiratory infection primarily caused by influenza A and B viruses, which circulate annually and cause substantial morbidity and mortality worldwide. Annual influenza vaccination is currently the most effective measure for preventing influenza and greatly reduces the risk of disease severity and the incidence of complications and death. Annual seasonal influenza vaccines are traditionally produced in Japan and many other countries using viruses propagated in embryonated chicken eggs. However, at present, the effectiveness of the seasonal influenza vaccines has some significant limitations, partly because of egg-adaptive mutations in the antigenic sites of the influenza virus haemagglutinin, which are caused by the continued evolution of seasonal influenza viruses. To overcome the limitations of egg-based influenza vaccine production, a mammalian cell culture-based influenza vaccine production system has been developed in Japan in the past decade as an alternative to the current production method. In this review, I have summarised the progress in the development of cell-based seasonal influenza vaccines and discussed the technological challenges encountered in the development of influenza vaccines.
Collapse
Affiliation(s)
- Itsuki Hamamoto
- Laboratory of Cell-based Vaccine Development, Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan
| |
Collapse
|
3
|
Serafin B, Kamen A, de Crescenzo G, Henry O. Antibody-independent surface plasmon resonance assays for influenza vaccine quality control. Appl Microbiol Biotechnol 2024; 108:307. [PMID: 38656587 PMCID: PMC11043112 DOI: 10.1007/s00253-024-13145-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 03/29/2024] [Accepted: 04/10/2024] [Indexed: 04/26/2024]
Abstract
Surface plasmon resonance (SPR)-based biosensors have emerged as a powerful platform for bioprocess monitoring due to their ability to detect biointeractions in real time, without the need for labeling. Paramount for the development of a robust detection platform is the immobilization of a ligand with high specificity and affinity for the in-solution species of interest. Following the 2009 H1N1 pandemic, much effort has been made toward the development of quality control platforms for influenza A vaccine productions, many of which have employed SPR for detection. Due to the rapid antigenic drift of influenza's principal surface protein, hemagglutinin, antibodies used for immunoassays need to be produced seasonally. The production of these antibodies represents a 6-8-week delay in immunoassay and, thus, vaccine availability. This review focuses on SPR-based assays that do not rely on anti-HA antibodies for the detection, characterization, and quantification of influenza A in bioproductions and biological samples. KEY POINTS: • The single radial immunodiffusion assay (SRID) has been the gold standard for the quantification of influenza vaccines since 1979. Due to antigenic drift of influenza's hemagglutinin protein, new antibody reagents for the SRID assay must be produced each year, requiring 6-8 weeks. The resulting delay in immunoassay availability is a major bottleneck in the influenza vaccine pipeline. This review highlights ligand options for the detection and quantification of influenza viruses using surface plasmon resonance biosensors.
Collapse
Affiliation(s)
- Benjamin Serafin
- Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada
| | - Amine Kamen
- Department of Bioengineering, McGill University, Montreal, QC, Canada
| | - Gregory de Crescenzo
- Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada
| | - Olivier Henry
- Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada.
| |
Collapse
|
4
|
Kang G, Kim M, Lee Y, Yang H, Seong BL, Jung H. Egg microneedles for transdermal vaccination of inactivated influenza virus. Biomater Sci 2024; 12:907-918. [PMID: 38174731 DOI: 10.1039/d3bm01635h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
The use of dissolving microneedles (DMNs) is a drug delivery technique in which drug dissolution occurs once it is administered into the skin. The skin is a remarkable site for vaccination due to its significant immunologic properties. Compared to the traditional hypodermic intramuscular (IM) injection, vaccination via DMN does not require cold chains and allows for minimal invasive drug delivery. On account of the significance of skin vaccination, preceding studies have been conducted to elucidate the importance of the DMN technology in vaccination. Most of these studies focused on formulations that maintain the activity of the vaccine, so formulations designed to be specific to the mechanical properties of the microneedle could not be used together independently. In this study, we have developed influenza vaccine loaded egg microneedles (EMN) and characterized the specificity of layer-specific functions of EMN by distinguishing between formulations that can maintain the activity of the vaccine and have the mechanical strength. By the use of in vitro tests such as ELISA and SRID assays, we quantitively evaluated the antigen activity of the formulation candidates to be 87% and 91%, respectively. In vivo tests were also conducted as mouse groups were inoculated with the formulation constructed into egg microneedles (FLU-EMN) to determine the protective efficacy against infection. The results demonstrated that FLU-EMN with functionalized formulations successfully enabled protective immune response even with a fractional dose compared to IM injection.
Collapse
Affiliation(s)
- Geonwoo Kang
- Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- Juvic Inc., 272 Digital-ro, Guro-gu, Seoul 08389, Republic of Korea
| | - Minkyung Kim
- Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
| | - Youjin Lee
- Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
| | - Huisuk Yang
- Juvic Inc., 272 Digital-ro, Guro-gu, Seoul 08389, Republic of Korea
| | - Baik-Lin Seong
- Department of Microbiology, College of Medicine, Yonsei University, Seoul, 03721, Republic of Korea
- Vaccine Innovative Technology Alliance (VITAL)-Korea, Yonsei University, Seoul 03721, Republic of Korea
| | - Hyungil Jung
- Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- Juvic Inc., 272 Digital-ro, Guro-gu, Seoul 08389, Republic of Korea
| |
Collapse
|
5
|
Donohue MP, Cao Z, Bowen T, Dickinson R, Zhang Y, Qian J. The CombE-IDMS Alternate Potency Method for H5N1 and H5N8 Cell-Based Vaccines. Vaccines (Basel) 2023; 11:1799. [PMID: 38140203 PMCID: PMC10747648 DOI: 10.3390/vaccines11121799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/14/2023] [Accepted: 11/23/2023] [Indexed: 12/24/2023] Open
Abstract
Assaying the potency of inactivated viral influenza vaccines is performed using single radial immunodiffusion, which is the globally accepted release method for potency. Under conditions of a rapidly emerging pandemic, such as the 2009 H1N1 influenza pandemic, a recognized obstacle in the delivery of vaccines to the public is the time needed for the distribution of calibrated SRID reagents (antisera and antigen standards) to vaccine manufacturers. Previously, we first described a novel streamlined MS-based assay, CombE-IDMS, which does not rely on antisera/antibodies or reference antigens, as a potential rapidly deployable alternate potency method through a comparison with SRID on adjuvanted seasonal quadrivalent vaccine cell-based (aQIVc) materials. In this report, we further demonstrate that the CombE-IDMS method can also be applied to measure the potency of pre-pandemic H5N1 and H5N8 monovalent vaccine materials, each subtype both unadjuvanted and adjuvanted, through a forced degradation study. Overall, CombE-IDMS results align with those of the gold standard SRID method on both H5N1 and H5N8 materials under conditions of thermal, pH, oxidative and freeze/thaw stress, lending further evidence for the CombE-IDMS method's suitability as an alternate assay for potency of both seasonal and pandemic influenza vaccines.
Collapse
Affiliation(s)
- Matthew P. Donohue
- Biopharmaceutical Product Development, CSL Seqirus, Holly Springs, NC 27540, USA; (Z.C.); (T.B.); (Y.Z.)
| | - Zhijun Cao
- Biopharmaceutical Product Development, CSL Seqirus, Holly Springs, NC 27540, USA; (Z.C.); (T.B.); (Y.Z.)
| | - Thomas Bowen
- Biopharmaceutical Product Development, CSL Seqirus, Holly Springs, NC 27540, USA; (Z.C.); (T.B.); (Y.Z.)
| | | | - Ying Zhang
- Biopharmaceutical Product Development, CSL Seqirus, Holly Springs, NC 27540, USA; (Z.C.); (T.B.); (Y.Z.)
| | - Jiang Qian
- Biopharmaceutical Product Development, CSL Seqirus, Holly Springs, NC 27540, USA; (Z.C.); (T.B.); (Y.Z.)
| |
Collapse
|
6
|
Narayan K, Paduraru C, Blake T, Arunachalam AB. Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies. Front Immunol 2023; 14:1128683. [PMID: 37457687 PMCID: PMC10344355 DOI: 10.3389/fimmu.2023.1128683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 06/07/2023] [Indexed: 07/18/2023] Open
Abstract
Potency testing and release of annual influenza vaccines require preparation, calibration, and distribution of reference antigens (RAs) and antisera every year, which takes an average of 8 to 12 weeks, and can be a major limiting factor in pandemic situations. Here we describe for the first time a robust Surface Plasmon Resonance (SPR)-based method that employs influenza subtype or lineage hemagglutinin (HA) specific monoclonal antibodies (mAbs) to measure the HA concentration in influenza multivalent vaccines. Implementing such an advanced test method will at the very least eliminate the rate-limiting and laborious efforts of making antisera reagents annually, and thus expedite the influenza vaccine delivery to the public by at least 6 weeks. Results demonstrate that the SPR-based method, developed using Biacore, is robust and not influenced by the type of RAs (inactivated whole virus, split, or subunit vaccine-derived materials), whether they are used as monovalent or multivalent preparations. HA concentrations obtained for monovalent drug substances (DS) or quadrivalent drug products (DP) of inactivated influenza split vaccine showed a tight correlation (the best fit value for the slope is 1.001 with R2 of 0.9815 and P-value <0.0001) with the corresponding values obtained by the current potency assay, Single Radial Immunodiffusion (SRID). Supplementary analysis of the results by the Bland-Altman plot demonstrated good agreement between the SPR and SRID methods, with no consistent bias of the SPR versus SRID method. We further demonstrate that the SPR-based method can be used to estimate HA concentrations in intermediates of the influenza vaccine manufacturing process containing varying matrices and impurity levels. Further, the results demonstrate that the method is sensitive to detecting degradation of HA caused by elevated temperature, low pH, and freezing. It is evident from this report and other published work that the advancement of analytical techniques and the early findings are encouraging for the implementation of alternate potency assays with far-reaching benefits covering both seasonal and pandemic influenza.
Collapse
|
7
|
Ekimov A, Arunachalam AB, Blake T, Bodle J, Couzens L, Dubey S, Eichelberger M, Engelhardt OG, Gubinelli F, Joshi M, Melnyk D, Palladino G, Rigsby P, Rockman S, Savina N, Smith E, Gilchrist SAN. Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine. Vaccine 2023:S0264-410X(23)00726-0. [PMID: 37344260 DOI: 10.1016/j.vaccine.2023.06.051] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 05/01/2023] [Accepted: 06/13/2023] [Indexed: 06/23/2023]
Abstract
Determination of the potency of a vaccine is critical to ensuring that an appropriate dose is delivered, lot-to-lot consistency is maintained, and that the formulation is stable over the life of the vaccine. The potency of inactivated influenza vaccines is determined routinely by the Single Radial Immunodiffusion (SRID) assay. A number of alternative potency assays have been proposed and have been under evaluation in recent years. The aim of this study was to compare a surface plasmon resonance-based assay and two different enzyme linked immunoassays against the current potency assay, SRID, and against mouse immunogenicity when haemagglutinin antigen of the A(H1N1)pdm09 component of an inactivated influenza vaccine is stressed by elevated temperature, low pH and freezing. This analysis demonstrated that the alternative assays had good correspondence with SRID for samples from most stress conditions and that the immunogenicity in mice corresponded with potency in SRID for all stress samples. Subject to further analysis, the assays have been shown to have the potential to possibly replace, and at least complement, SRID.
Collapse
Affiliation(s)
- Aleksei Ekimov
- Department of New Technologies, Federal State Unitary Enterprise (FSUE), Saint-Petersburg Scientific Research Institute of Vaccines and Serums (SPbSRIVS), Federal Medical-Biological Agency (FMBA) of Russia, Saint-Petersburg 198320, Russian Federation.
| | - Arun B Arunachalam
- Global Analytical Sciences, R&D Sanofi, 1 Discovery Dr, Swiftwater, PA 18370, USA.
| | - Taylor Blake
- Global Analytical Sciences, R&D Sanofi, 1 Discovery Dr, Swiftwater, PA 18370, USA.
| | - Jesse Bodle
- Technical Development and Global Process Innovation, Seqirus Ltd, 63 Poplar Rd, Parkville, Victoria 3052, Australia.
| | - Laura Couzens
- Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America.
| | - Sitara Dubey
- Standards Lifecycle, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK.
| | - Maryna Eichelberger
- Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America.
| | - Othmar G Engelhardt
- Vaccines, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK.
| | - Francesco Gubinelli
- Standards Lifecycle, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK.
| | - Manju Joshi
- Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America.
| | - Darya Melnyk
- Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America.
| | - Giuseppe Palladino
- Preclinical Research, Seqirus, 50 Hampshire Street, 9th Floor Cambridge, MA 02139, United States of America.
| | - Peter Rigsby
- Analytical and Biological Sciences, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK.
| | - Steven Rockman
- Technical Development and Global Process Innovation, Seqirus Ltd, 63 Poplar Rd, Parkville, Victoria 3052, Australia.
| | - Natalya Savina
- Department of New Technologies, Federal State Unitary Enterprise (FSUE), Saint-Petersburg Scientific Research Institute of Vaccines and Serums (SPbSRIVS), Federal Medical-Biological Agency (FMBA) of Russia, Saint-Petersburg 198320, Russian Federation.
| | - Elena Smith
- Analytical CMC, Vaccine mRNA Center of Excellence, Sanofi, 200 West Street, Waltham, MA 02451, United States of America.
| | - Shawn A N Gilchrist
- S Gilchrist Consulting Services Inc, 8 Covebank Crescent, Brampton, ON L6P 2X5, Canada.
| |
Collapse
|
8
|
Cacciottolo M, Nice JB, Li Y, LeClaire MJ, Twaddle R, Mora CL, Adachi SY, Chin ER, Young M, Angeles J, Elliott K, Sun M. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins. Microbiol Spectr 2023; 11:e0050323. [PMID: 37093009 PMCID: PMC10269692 DOI: 10.1128/spectrum.00503-23] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 04/03/2023] [Indexed: 04/25/2023] Open
Abstract
Currently approved vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused solely on the spike protein to provide immunity. The first vaccines were developed rapidly using spike mRNA delivered by lipid nanoparticles but required ultralow-temperature storage and have had limited immunity against variations in spike. Subsequently, protein-based vaccines were developed, which offer broader immunity but require significant time for development and the use of an adjuvant to boost the immune response. Here, exosomes were used to deliver a bivalent protein-based vaccine in which two independent viral proteins were used. Exosomes were engineered to express either SARS-CoV-2 delta spike (Stealth X-Spike [STX-S]) or the more conserved nucleocapsid (Stealth X-Nucleocapsid [STX-N]) protein on the surface. When administered as a single product (STX-S or STX-N) or in combination (STX-S+N), both STX-S and STX-N induced strong immunization with the production of potent humoral and cellular immune responses. Interestingly, these results were obtained with the administration of only nanograms of protein and without an adjuvant. In two independent animal models (mouse and rabbit), the administration of nanograms of the STX-S+N vaccine resulted in increased antibody production, potent neutralizing antibodies with cross-reactivity to other variants of spike, and strong T-cell responses. Importantly, no competition of immune responses was observed, allowing the delivery of nucleocapsid with spike to offer improved SARS-CoV-2 immunity. These data show that the StealthX exosome platform has the enormous potential to revolutionize vaccinology by combining the advantages of mRNA and recombinant protein vaccines into a superior, rapidly generated, low-dose vaccine resulting in potent, broader immunity. IMPORTANCE The pandemic emergency has brought to light the need for a new generation of rapidly developed vaccines that induce longer-lasting, potent, and broader immune responses. While the mRNA vaccines played a critical role during the emergency in reducing SARS-CoV-2 hospitalization rates and deaths, more efficient approaches are needed. A multivalent, protein-based vaccine delivered by exosomes could meet this urgent need due to the high speed of development, manufacturability, and the ability to produce a strong antibody response, with neutralizing antibodies and a strong T-cell response able to broadly combat viral infection with a minimum number of injections.
Collapse
Affiliation(s)
| | - Justin B Nice
- Capricor Therapeutics, Inc., San Diego, California, USA
| | - Yujia Li
- Capricor Therapeutics, Inc., San Diego, California, USA
| | | | - Ryan Twaddle
- Capricor Therapeutics, Inc., San Diego, California, USA
| | - Ciana L. Mora
- Capricor Therapeutics, Inc., San Diego, California, USA
| | | | | | | | - Jenna Angeles
- Capricor Therapeutics, Inc., San Diego, California, USA
| | | | - Minghao Sun
- Capricor Therapeutics, Inc., San Diego, California, USA
| |
Collapse
|
9
|
Jhingree JR, Boisvert J, Mercier G. An isotope dilution mass spectrometry assay to track Norovirus-like particles in vaccine process intermediates by quantifying capsid protein VP1. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2023; 15:2729-2735. [PMID: 37199095 DOI: 10.1039/d3ay00411b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
The coronavirus disease (COVID-19) pandemic shows the rapid pace at which vaccine development can occur which highlights the need for more fast and efficient analytical methodologies to track and characterize candidate vaccines during manufacturing and purification processes. The candidate vaccine in this work comprises plant-derived Norovirus-like particles (NVLPs) which are structures that mimic the virus but lack any infectious genetic material. Presented here is a liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology for the quantification of viral protein VP1, the main component of the NVLPs in this study. It combines isotope dilution mass spectrometry (IDMS) with multiple reaction monitoring (MRM) to quantify targeted peptides in process intermediates. Multiple MRM transitions (precursor/product ion pairs) for VP1 peptides were tested with varying MS source conditions and collision energies. Final parameter selection for quantification includes three peptides with two MRM transitions each offering maximum detection sensitivity under optimized MS conditions. For quantification, a known concentration of the isotopically labeled version of the peptides to be quantified was added into working standard solutions to serve as an internal standard (IS); calibration curves were generated for concentration of native peptide vs. the peak area ratio of native-to-isotope labeled peptide. VP1 peptides in samples were quantified with labeled versions of the peptides added at the same level as that of the standards. Peptides were quantified with limit of detection (LOD) as low as 1.0 fmol μL-1 and limit of quantitation (LOQ) as low as 2.5 fmol μL-1. NVLP preparations spiked with known quantities of either native peptides or drug substance (DS) comprising assembled NVLPs produced recoveries indicative of minimal matrix effects. Overall, we report a fast, specific, selective, and sensitive LC-MS/MS strategy to track NVLPs through the purification steps of the DS of a Norovirus candidate vaccine. To the best of our knowledge, this is the first application of an IDMS method to track virus-like particles (VLPs) produced in plants as well as measurements performed with VP1, a Norovirus capsid protein.
Collapse
Affiliation(s)
- Jacquelyn R Jhingree
- Medicago Inc., 2552 Boulevard du Parc-Technologique, Québec, QC, G1P 4S6, Canada.
| | - Julie Boisvert
- Medicago Inc., 2552 Boulevard du Parc-Technologique, Québec, QC, G1P 4S6, Canada.
| | - Geneviève Mercier
- Medicago Inc., 2552 Boulevard du Parc-Technologique, Québec, QC, G1P 4S6, Canada.
| |
Collapse
|
10
|
Thompson AC, Wills RW, Smith DR. Sources of variance in the results of a commercial bovine immunoglobulin G radial immunodiffusion assay. J Vet Diagn Invest 2023; 35:34-41. [PMID: 36416388 PMCID: PMC9751470 DOI: 10.1177/10406387221140047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Radial immunodiffusion (RID) is used to quantify IgG concentration in neonatal beef or dairy calf serum; variability has been noted that may affect the precision and accuracy of assay results. We determined the source, range, and homogeneity of variance in the results of a commercial bovine IgG RID assay (Triple J Farm). To estimate the variance in the precipitin ring diameter, we used 6 sera, measured 28 times across 8 plates and 4 lots, and 3 standards with known IgG concentrations, measured 75 times across 69 plates and 5 lots. The source of diameter variance was determined using variance partition coefficients for lot, plate, and repetition. We used 11 different methods to generate standard curves to convert RID precipitin ring diameters to IgG concentrations. The Levene test of homogeneity of variance (α = 0.1) was used to evaluate the equality of variance between the standards or serum precipitin ring diameters and calculated IgG concentrations. Lot and plate contributed minimally to the diameter variance. Precipitin ring diameters had equal variance. Calculated IgG concentrations for serum not requiring dilution had equal variance. A linear equation from aggregated standards, performed within the same day, had greater accuracy for the calculated IgG concentrations of the standards compared to other equation methods. Regardless of standard curve methodology or IgG concentration, variability inherent to the assay limits its clinical usefulness.
Collapse
Affiliation(s)
- Alexis C. Thompson
- Departments of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, USA
| | - Robert W. Wills
- Comparative Biomedical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, USA
| | - David R. Smith
- Departments of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, USA
| |
Collapse
|
11
|
Bodle J, Vandenberg K, Laurie K, Barr IG, Zhang Y, Rockman S. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines. Front Immunol 2023; 14:1147028. [PMID: 37033922 PMCID: PMC10073703 DOI: 10.3389/fimmu.2023.1147028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 03/07/2023] [Indexed: 04/11/2023] Open
Abstract
Background The current compendial assay for haemagglutinin antigen potency in influenza vaccine is the single radial immunodiffusion (SRID) which is time consuming and can lead to delays in release of vaccine. We previously described an alternate capture and detection enzyme linked immunoassay (ELISA) that utilizes sub-type specific, sub-clade cross-reactive monoclonal antibodies (mAbs) that are haemagglutination inhibiting (HAI) and correlate with SRID. The aim of this study is to determine the applicability of ELISA across current platforms for quantitation of seasonal quadrivalent vaccine. Methods A single mAb capture and detection ELISA was employed to quantitate hemagglutinin (HA) derived from different vaccine platforms and host organisms and compared to SRID and a polyclonal antibody based ELISA. Results We selected mAbs that displayed appropriate characteristics for a stability indicating potency assay which reacted to avian, insect and mammalian derived HA. Qualification of the homologous mAb assay against egg and cell derived HA demonstrated performance similar to that of the SRID however, superiority in sensitivity and specificity against strains from both influenza B/Victoria and B/Yamagata lineages. Analysis of drifted strains across multiple seasons demonstrated continued utility of this approach, reducing the need to develop reagents each season. With modification of the assay, we were able to accurately measure HA from different platforms and process stages using a single calibrated reference standard. We demonstrated the accuracy of ELISA when testing vaccine formulations containing selected adjuvants at standard and higher concentrations. Accelerated stability analysis indicated a strong correlation in the rate of degradation between the homologous mAb ELISA and SRID but not with ELISA utilizing polyclonal antisera. Further, we demonstrated specificity was restricted to the trimeric and oligomeric forms of HA but not monomeric HA. Conclusion We believe this homologous mAb ELISA is a suitable replacement for the SRID compendial assay for HA antigen quantitation and stability assessment. Identification of suitable mAbs that are applicable across multiple vaccine platforms with extended sub-type reactivity across a number of influenza seasons, indicate that this assay has broad applicability, leading to earlier availability of seasonal and pandemic vaccines without frequent replacement of polyclonal antisera that is required with SRID.
Collapse
Affiliation(s)
- Jesse Bodle
- Vaccine Product Development, CSL Seqirus Ltd, Parkville, VIC, Australia
- *Correspondence: Jesse Bodle,
| | | | - Karen Laurie
- Vaccine Product Development, CSL Seqirus Ltd, Parkville, VIC, Australia
| | - Ian G. Barr
- Collaborating Centre for Reference and Research on Influenza, World Health Organisation, Melbourne, VIC, Australia
| | - Ying Zhang
- Vaccine Product Development, CSL Seqirus Ltd, Holly Springs, NC, United States
| | - Steven Rockman
- Vaccine Product Development, CSL Seqirus Ltd, Parkville, VIC, Australia
- Department of Immunology and Microbiology, University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
12
|
Cheung CY, Dubey S, Hadrovic M, Ball CR, Ramage W, McDonald JU, Harvey R, Hufton SE, Engelhardt OG. Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies. Vaccines (Basel) 2022; 10:vaccines10091473. [PMID: 36146550 PMCID: PMC9503116 DOI: 10.3390/vaccines10091473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 08/22/2022] [Accepted: 08/25/2022] [Indexed: 11/16/2022] Open
Abstract
Inactivated vaccines are the main influenza vaccines used today; these are usually presented as split (detergent-disrupted) or subunit vaccines, while whole-virus-inactivated influenza vaccines are rare. The single radial immune diffusion (SRD) assay has been used as the gold standard potency assay for inactivated influenza vaccines for decades; however, more recently, various alternative potency assays have been proposed. A new potency test should be able to measure the amount of functional antigen in the vaccine, which in the case of influenza vaccines is the haemagglutinin (HA) protein. Potency tests should also be able to detect the loss of potency caused by changes to the structural and functional integrity of HA. To detect such changes, most alternative potency tests proposed to date use antibodies that react with native HA. Due to the frequent changes in influenza vaccine composition, antibodies may need to be updated in line with changes in vaccine viruses. We have developed two ELISA-based potency assays for group 1 influenza A viruses using cross-reactive nanobodies. The nanobodies detect influenza viruses of subtype H1N1 spanning more than three decades, as well as H5N1 viruses, in ELISA. We found that the new ELISA potency assays are sensitive to the nature of the reference antigen (standard) used to quantify vaccine antigens; using standards matched in their presentation to the vaccine type improved correspondence between the ELISA and SRD assays.
Collapse
Affiliation(s)
- Chung Y. Cheung
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Sitara Dubey
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Martina Hadrovic
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Christina R. Ball
- Biotherapeutics Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Walter Ramage
- Biotherapeutics Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Jacqueline U. McDonald
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Ruth Harvey
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Simon E. Hufton
- Biotherapeutics Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
| | - Othmar G. Engelhardt
- Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar EN6 3QG, UK
- Correspondence:
| |
Collapse
|
13
|
Chia MY, Lin CY, Chen PL, Lai CC, Weng TC, Sung WC, Hu AYC, Lee MS. Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform. Viruses 2022; 14:v14091937. [PMID: 36146744 PMCID: PMC9502495 DOI: 10.3390/v14091937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 08/29/2022] [Accepted: 08/30/2022] [Indexed: 11/16/2022] Open
Abstract
Human infections with avian-origin H7N9 influenza A viruses were first reported in China, and an approximately 38% human mortality rate was described across six waves from February 2013 to September 2018. Vaccination is one of the most cost-effective ways to reduce morbidity and mortality during influenza epidemics and pandemics. Egg-based platforms for the production of influenza vaccines are labor-intensive and unable to meet the surging demand during pandemics. Therefore, cell culture-based technology is becoming the alternative strategy for producing influenza vaccines. The current influenza H7N9 vaccine virus (NIBRG-268), a reassortant virus from A/Anhui/1/2013 (H7N9) and egg-adapted A/PR/8/34 (H1N1) viruses, could grow efficiently in embryonated eggs but not mammalian cells. Moreover, a freezing-dry formulation of influenza H7N9 vaccines with long-term stability will be desirable for pandemic preparedness, as the occurrence of influenza H7N9 pandemics is not predictable. In this study, we adapted a serum-free anchorage-independent suspension Madin-Darby Canine Kidney (MDCK) cell line for producing influenza H7N9 vaccines and compared the biochemical characteristics and immunogenicity of three influenza H7N9 vaccine antigens produced using the suspension MDCK cell-based platform without freeze-drying (S-WO-H7N9), the suspension MDCK cell-based platform with freeze-drying (S-W-H7N9) or the egg-based platform with freeze-drying (E-W-H7N9). We demonstrated these three vaccine antigens have comparable biochemical characteristics. In addition, these three vaccine antigens induced robust and comparable neutralizing antibody (NT; geometric mean between 1016 and 4064) and hemagglutinin-inhibition antibody (HI; geometric mean between 640 and 1613) titers in mice. In conclusion, the serum-free suspension MDCK cell-derived freeze-dried influenza H7N9 vaccine is highly immunogenic in mice, and clinical development is warranted.
Collapse
Affiliation(s)
- Min-Yuan Chia
- Department of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Chun-Yang Lin
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Po-Ling Chen
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Chia-Chun Lai
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Tsai-Chuan Weng
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Wang-Chou Sung
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Alan Yung-Chih Hu
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
| | - Min-Shi Lee
- National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, Taiwan
- Correspondence: ; Tel.: +886-(37)-246-166 (ext. 35520); Fax: +886-(37)-583-009
| |
Collapse
|
14
|
Rockman S, Taylor B, McCauley JW, Barr IG, Longstaff R, Bahra R. Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience. Vaccines (Basel) 2022; 10:vaccines10040589. [PMID: 35455338 PMCID: PMC9024617 DOI: 10.3390/vaccines10040589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 04/05/2022] [Accepted: 04/06/2022] [Indexed: 11/16/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease. The severe impact on the health system and the high economic cost of non-pharmaceutical interventions, such as lockdowns and international border closures employed to mitigate the spread of COVID-19 prior to the arrival of effective vaccines, have led to calls for development and deployment of novel vaccine technologies as part of a “100-day response ambition” for the next pandemic. Prior to COVID-19, all of the pandemics (excluding HIV) in the past century have been due to influenza viruses, and influenza remains one of the most likely future pandemic threats along with new coronaviruses. New and emerging vaccine platforms are likely to play an important role in combatting the next pandemic. However, the existing well-established, proven platforms for seasonal and pandemic influenza manufacturing will also continue to be utilized to rapidly address the next influenza threat. The field of influenza vaccine manufacturing has a long history of successes, including approval of vaccines within approximately 100 days after WHO declaration of the A(H1N1) 2009 influenza pandemic. Moreover, many advances in vaccine science and manufacturing capabilities have been made in the past decade to optimize a rapid and timely response should a new influenza pandemic threat emerge.
Collapse
Affiliation(s)
- Steven Rockman
- Seqirus Ltd., Parkville, VIC 3052, Australia
- Department of Immunology and Microbiology, University of Melbourne, Parkville, VIC 3052, Australia
- Correspondence: ; Tel.: +61-3-9389-2712
| | - Beverly Taylor
- Seqirus Ltd., Maidenhead SL6 8AA, UK; (B.T.); (R.L.); (R.B.)
| | | | - Ian G. Barr
- WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, VIC 3000, Australia;
| | - Ray Longstaff
- Seqirus Ltd., Maidenhead SL6 8AA, UK; (B.T.); (R.L.); (R.B.)
| | - Ranbir Bahra
- Seqirus Ltd., Maidenhead SL6 8AA, UK; (B.T.); (R.L.); (R.B.)
| |
Collapse
|
15
|
Clinical Development of mRNA Vaccines: Challenges and Opportunities. Curr Top Microbiol Immunol 2022; 440:167-186. [PMID: 35906319 DOI: 10.1007/82_2022_259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The emergence of safe and effective mRNA platform-based COVID-19 vaccines from the recent pandemic has changed the face of vaccine development. Compared with conventional technologies used historically, mRNA-based vaccines offer a rapid flexible and robust approach to preventing disease caused by transient viral strains such as SAR2-CoV-2 variants of concern and seasonal influenza. Adaptations in the formulation of the mRNA delivery systems such as with lipid nanoparticle delivery (LNP) used in mRNA-1273 and BNT16b2b have enabled this technology to flourish under the urgent collective response and collaborative regulatory understanding derived from COVID-19 vaccine development. The application of mRNA-based therapeutics in other areas holds potential promise including combination vaccines that might deliver protections against multiple infectious diseases. Future studies and further advances in mRNA-based technologies will provide insight into the clinical efficacy and real-world effectiveness of vaccines as well as provisions with respect to the impact of reactogenicity profiles. Overall, the success of mRNA-based COVID-19 vaccines has helped unlock a platform likely to result in many more candidate vaccines entering clinical evaluation to address the unmet medical needs of other diseases including viral respiratory diseases, herpesviruses, and historically challenging vaccine targets such as HIV.
Collapse
|
16
|
van den Biggelaar RHGA, Hoefnagel MHN, Vandebriel RJ, Sloots A, Hendriksen CFM, van Eden W, Rutten VPMG, Jansen CA. Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Rev Vaccines 2021; 20:1221-1233. [PMID: 34550041 DOI: 10.1080/14760584.2021.1977628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Before release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still largely rely on in vivo methods. Improved vaccine production processes, ethical concerns, and suboptimal performance of some in vivo tests have led to the development of in vitro alternatives. AREAS COVERED This review describes the scientific constraints that need to be overcome for replacement of in vivo batch tests, as well as potential solutions. Topics include the critical quality attributes of vaccines that require testing, the use of cell-based assays to mimic aspects of in vivo vaccine-induced immune responses, how difficulties with testing adjuvanted vaccines in vitro can be overcome, the use of altered batches to validate new in vitro test methods, and how cooperation between different stakeholders is key to moving the transition forward. EXPERT OPINION For safety testing, many in vitro alternatives are already available or at an advanced level of development. For potency testing, in vitro alternatives largely comprise immunochemical methods that assess several, but not all critical vaccine properties. One-to-one replacement by in vitro alternatives is not always possible and a combination of methods may be required.
Collapse
Affiliation(s)
- Robin H G A van den Biggelaar
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | | | - Rob J Vandebriel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Arjen Sloots
- Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands
| | | | - Willem van Eden
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Victor P M G Rutten
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.,Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa
| | - Christine A Jansen
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.,Cell Biology and Immunology Group, Department of Animal Sciences, Wageningen University and Research, Wageningen, The Netherlands
| |
Collapse
|
17
|
Nuwarda RF, Alharbi AA, Kayser V. An Overview of Influenza Viruses and Vaccines. Vaccines (Basel) 2021; 9:1032. [PMID: 34579269 PMCID: PMC8473132 DOI: 10.3390/vaccines9091032] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 09/12/2021] [Accepted: 09/13/2021] [Indexed: 01/12/2023] Open
Abstract
Influenza remains one of the major public health concerns because it causes annual epidemics and can potentially instigate a global pandemic. Numerous countermeasures, including vaccines and antiviral treatments, are in use against seasonal influenza infection; however, their effectiveness has always been discussed due to the ongoing resistance to antivirals and relatively low and unpredictable efficiency of influenza vaccines compared to other vaccines. The growing interest in vaccines as a promising approach to prevent and control influenza may provide alternative vaccine development options with potentially increased efficiency. In addition to currently available inactivated, live-attenuated, and recombinant influenza vaccines on the market, novel platforms such as virus-like particles (VLPs) and nanoparticles, and new vaccine formulations are presently being explored. These platforms provide the opportunity to design influenza vaccines with improved properties to maximize quality, efficacy, and safety. The influenza vaccine manufacturing process is also moving forward with advancements relating to egg- and cell-based production, purification processes, and studies into the physicochemical attributes and vaccine degradation pathways. These will contribute to the design of more stable, optimized vaccine formulations guided by contemporary analytical testing methods and via the implementation of the latest advances in the field.
Collapse
Affiliation(s)
| | | | - Veysel Kayser
- Faculty of Medicine and Health, Sydney Pharmacy School, The University of Sydney, Sydney, NSW 2006, Australia; (R.F.N.); (A.A.A.)
| |
Collapse
|
18
|
Sparrow E, Wood JG, Chadwick C, Newall AT, Torvaldsen S, Moen A, Torelli G. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine 2021; 39:512-520. [PMID: 33341308 PMCID: PMC7814984 DOI: 10.1016/j.vaccine.2020.12.018] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 11/30/2020] [Accepted: 12/06/2020] [Indexed: 12/19/2022]
Abstract
Vaccines will be an important element in mitigating the impact of an influenza pandemic. While research towards developing universal influenza vaccines is ongoing, the current strategy for vaccine supply in a pandemic relies on seasonal influenza vaccine production to be switched over to pandemic vaccines. Understanding how much vaccine could be produced, in which regions of the world and in what timeframe is critical to informing influenza pandemic preparedness. Through the Global Action Plan for Influenza Vaccines, 2006-2016, WHO promoted an increase in vaccine production capacity and monitors the landscape through periodically surveying influenza vaccine manufacturers. This study compares global capacity for production of influenza vaccines in 2019 with estimates from previous surveys; provides an overview of countries with established production facilities; presents vaccine production by type and manufacturing process; and discusses limitations to these estimates. Results of the current survey show that estimated annual seasonal influenza vaccine production capacity changed little since 2015 increasing from 1.47 billion to 1.48 billion doses with potential maximum annual influenza pandemic vaccine production capacity increasing from 6.37 billion to 8.31 billion doses. However, this figure should be interpreted with caution as it presents a best-case scenario with several assumptions which may impact supply. Further, pandemic vaccines would not be immediately available and could take four to six months for first supplies with several more months needed to reach maximum capacity. A moderate-case scenario is also presented of 4.15 billion doses of pandemic vaccine in 12 months. It is important to note that two doses of pandemic vaccine are likely to be required to elicit an adequate immune response. Continued efforts are needed to ensure the sustainability of this production and to conduct research for vaccines that are faster to produce and more broadly protective taking into account lessons learned from COVID-19 vaccine development.
Collapse
Affiliation(s)
- Erin Sparrow
- The World Health Organization, Geneva, Switzerland; School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia.
| | - James G Wood
- School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia
| | - Christopher Chadwick
- The World Health Organization, Geneva, Switzerland; Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland
| | - Anthony T Newall
- School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia
| | - Siranda Torvaldsen
- School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia; Women and Babies Research, The University of Sydney Northern Clinical School, NSW, Australia
| | - Ann Moen
- The World Health Organization, Geneva, Switzerland
| | | |
Collapse
|
19
|
HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC. Vaccine 2020; 39:545-553. [PMID: 33341306 DOI: 10.1016/j.vaccine.2020.12.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/20/2020] [Accepted: 12/01/2020] [Indexed: 11/23/2022]
Abstract
The only effective measure to decrease morbidity and mortality caused by the influenza virus in the human population is worldwide vaccination. Vaccination produces neutralizing antibodies that target the HA1 subunit of the HA (hemagglutinin) protein and are strain specific. The effectiveness of new influenza vaccines are linked to two factors, the correct prediction of the circulating strains in the population in a particular season and the concentration of the HA1 protein in the vaccine formulation. With the advent of the licensing of quadrivalent vaccines, pharmaceutical manufacturers are under considerable pressure due to time constraints and dedicated resources to deliver 194-198 million doses (2020-2021 U.S. market) of vaccine. Considering the valuable resources needed to produce the influenza vaccine in a timely manner, the efficient quantitation of the HA1 protein (the main component in the influenza vaccine) is required. Currently the only method approved by regulatory agencies for quantitation of the HA antigen in vaccines is the single radial immunodiffusion assay (SRID), an antibody dependent assay that is not time efficient. Time efficient methods that are antibody independent e.g. reverse phase-high performance liquid chromatography (RP-HPLC) or size exclusion-HPLC (SE-HPLC) are available. An improved method implementing reverse phase-ultra performance liquid chromatography (RP-UPLC) has been developed to quantitate the HA1 protein antigen present in the high yield reassortant vaccine seed viruses from influenza A H1N1 and H3N2 subtypes harvested from inoculated embryonated chicken eggs. This method differentiates between high yield and lower yielding reassortants in order to select the best vaccine candidate seed virus with the highest growth 'in ovo'. This direct capability to monitor the HA1 concentration of potential reassortant seed viruses and to choose the best yielding HA influenza reassortant when faced with multiple viral seed candidates provides a major advantage on the industrial scale to the influenza vaccine process.
Collapse
|
20
|
Takahashi H, Fujimoto T, Horikoshi F, Uotani T, Okutani M, Shimasaki N, Hamamoto I, Odagiri T, Nobusawa E. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard. Biologicals 2020; 68:32-39. [PMID: 33023810 DOI: 10.1016/j.biologicals.2020.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 09/04/2020] [Accepted: 09/06/2020] [Indexed: 10/23/2022] Open
Abstract
In Japan, the practical application of completely cell-based seasonal influenza vaccines is under consideration. Considering the good correlation between the immunogenicity of egg-based influenza vaccines and the hemagglutinin (HA) content determined by the single radial immunodiffusion (SRD) assay, we determined the potency of the first cell-based quadrivalent vaccine experimentally generated in Japan using the SRD assay in this study. A primary liquid standard (PLS) and reference antigen were generated from the purified vaccine virus, and a sheep antiserum was produced against the HA of the vaccine virus. Since the purity of the PLS affects the reliability of vaccine potency testing, the purification steps are significant. We successfully prepared a purified PLS nearly free of cell debris. The HA content in the PLS was first estimated from the total amount of viral protein and the percentage of HA content determined by SDS-PAGE analysis. The HA content in the reference antigen was calibrated to that in the PLS via the SRD assay. The vaccine potency, that is, the HA content in each vaccine, was finally measured using the corresponding reference antigen. Ultimately, the measured vaccine potency of the monovalent vaccine was similar to that of the quadrivalent vaccine.
Collapse
Affiliation(s)
- Hitoshi Takahashi
- Influenza Virus Research Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan
| | - Takao Fujimoto
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Kagawa, Japan
| | - Fumiaki Horikoshi
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Kagawa, Japan
| | - Tae Uotani
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Kagawa, Japan
| | - Mie Okutani
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Kagawa, Japan
| | - Noriko Shimasaki
- Influenza Virus Research Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan
| | - Itsuki Hamamoto
- Influenza Virus Research Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan
| | - Takato Odagiri
- Influenza Virus Research Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan
| | - Eri Nobusawa
- Influenza Virus Research Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan.
| |
Collapse
|
21
|
Cooper HC, Xie Y, Palladino G, Barr JR, Settembre EC, Wen Y, Williams TL. Limited Tryptic Digestion-Isotope Dilution Mass Spectrometry (LTD-IDMS): A Reagent-Free Analytical Assay To Quantify Hemagglutinin of A(H5N1) Vaccine Material. Anal Chem 2020; 92:11879-11887. [PMID: 32867501 DOI: 10.1021/acs.analchem.0c02252] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Avian influenza viruses, such as A(H5N1) and A(H7N9), are primary public health concerns due to their pandemic potential. Influenza vaccines represent the most effective response to this threat especially with timely provision. The current pandemic response timelines require a substantial period for strain-specific reference antigen and sera preparation for use with single-radial immunodiffusion (SRID), the accepted vaccine potency assay. To address this time lag, the isotope dilution mass spectrometry (IDMS) method was developed to quantify the absolute hemagglutinin (HA, the main influenza antigen) amount in the vaccine without the need for purified, inactivated, and calibrated virus reference antigens. However, an additional challenge in determining potency is to differentiate between vaccine antigens in their most potent form from other less potent, stressed antigen forms. The limited trypsin digestion (LTD) method has been developed and does not require strain-specific full-length reference antigens or antibodies; instead, stressed HA is selectively degraded, leaving the more potent form to be measured. LTD, followed by precipitation and IDMS, allows for efficient differentiation between potent and significantly less potent HA for vaccine release and potency testing across the vaccine's shelf life. In this study, we tested the LTD-IDMS assay on A(H5N1) vaccine material that had been stressed by low pH, heat, and multiple freeze-thaw cycles. The results showed that the LTD-IDMS method effectively quantified the potent HA in A(H5N1) vaccine material with results comparable to SRID. As such, it shows great promise to complement and potentially replace SRID in a pandemic when strain-specific reagents may not be readily available.
Collapse
Affiliation(s)
- Hans C Cooper
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, United States
| | - Yuhong Xie
- Seqirus, a CSL Company, 50 Hampshire Street, Cambridge, Massachusetts 02139, United States
| | - Giuseppe Palladino
- Seqirus, a CSL Company, 50 Hampshire Street, Cambridge, Massachusetts 02139, United States
| | - John R Barr
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, United States
| | - Ethan C Settembre
- Seqirus, a CSL Company, 50 Hampshire Street, Cambridge, Massachusetts 02139, United States
| | - Yingxia Wen
- Seqirus, a CSL Company, 50 Hampshire Street, Cambridge, Massachusetts 02139, United States
| | - Tracie L Williams
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, United States
| |
Collapse
|
22
|
Rockman S, Laurie K, Barr I. Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now? Vaccines (Basel) 2020; 8:E211. [PMID: 32392812 PMCID: PMC7349738 DOI: 10.3390/vaccines8020211] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 05/01/2020] [Accepted: 05/06/2020] [Indexed: 11/16/2022] Open
Abstract
In 2009, a novel A(H1N1) influenza virus emerged with rapid human-to-human spread and caused the first pandemic of the 21st century. Although this pandemic was considered mild compared to the previous pandemics of the 20th century, there was still extensive disease and death. This virus replaced the previous A(H1N1) and continues to circulate today as a seasonal virus. It is well established that vaccines are the most effective method to alleviate the mortality and morbidity associated with influenza virus infections, but the 2009 A(H1N1) influenza pandemic, like all significant infectious disease outbreaks, presented its own unique set of problems with vaccine supply and demand. This manuscript describes the issues that confronted governments, international agencies and industries in developing a well-matched vaccine in 2009, and identifies the key improvements and remaining challenges facing the world as the next influenza pandemic inevitably approaches.
Collapse
Affiliation(s)
- Steven Rockman
- Seqirus, 63 Poplar Road, Parkville 3052, Victoria, Australia; (S.R.); (K.L.)
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, 792 Elizabeth Street, Melbourne 3000, Victoria, Australia
| | - Karen Laurie
- Seqirus, 63 Poplar Road, Parkville 3052, Victoria, Australia; (S.R.); (K.L.)
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, 792 Elizabeth Street, Melbourne 3000, Victoria, Australia
| | - Ian Barr
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, 792 Elizabeth Street, Melbourne 3000, Victoria, Australia
- WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne 3000, Victoria, Australia
| |
Collapse
|
23
|
Lemieux M, Lorbetskie B, Luebbert C, Walrond L, Li C, Li X, Cyr T, Sauvé S, Johnston M, Farnsworth A. The differential effect of sub-micron level HA aggregates on influenza potency assays. Vaccine 2019; 37:5276-5287. [DOI: 10.1016/j.vaccine.2019.07.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 07/09/2019] [Accepted: 07/13/2019] [Indexed: 10/26/2022]
|
24
|
Lorbetskie B, Cunningham AM, Lemieux M, Durno L, Farnsworth A, Wang J, Li C, Li X, Gilbert M, Sauvé S, Girard M. Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay. Anal Chem 2019; 91:8908-8917. [PMID: 31251585 DOI: 10.1021/acs.analchem.9b00617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Influenza vaccine potency is determined by the quantification of immunologically active hemagglutinin capable of eliciting neutralizing antibodies upon immunization. Currently, the single radial immunodiffusion (SRID) method is the standard in vitro potency assay used for lot release of seasonal inactivated influenza vaccines. Despite the proven usage of SRID, significant limitations such as the time-consuming preparation of reagents and limited dynamic range warrant the need for the development of alternative potency assays. Such alternative approaches need to discriminate and quantify relevant hemagglutinin material, provide strain identity, and be independent of strain-specific and seasonal reagents. Herein, we present a proof of concept method that combines the capture of conformationally well-folded hemagglutinin via a sialic acid binding step with the resolving power of reversed-phase high-performance liquid chromatography for strain identity and determination. Details of the protocol for the selective capture of receptor-binding hemagglutinin, its release from the receptor, and its relative determination are presented. This approach was found to provide flexibility for the reagents to be used and was adaptable to varying strain compositions of influenza vaccines. This proof of concept approach was developed as an antibody-independent methodology.
Collapse
Affiliation(s)
- Barry Lorbetskie
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| | - Anna-Maria Cunningham
- National Research Council Canada , Human Health Therapeutics Research Centre , Ottawa , Ontario K1A 0R6 , Canada
| | - Michèle Lemieux
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| | - Laura Durno
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| | - Aaron Farnsworth
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| | - Junzhi Wang
- National Institutes for Food and Drug Control and WHO Collaborating Center for Standardization and Evaluation of Biologicals , National Institute for Food and Drug Control of China , No.2 Tiantan Xili , Beijing 10050 , People's Republic of China
| | - Changgui Li
- National Institutes for Food and Drug Control and WHO Collaborating Center for Standardization and Evaluation of Biologicals , National Institute for Food and Drug Control of China , No.2 Tiantan Xili , Beijing 10050 , People's Republic of China
| | - Xuguang Li
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada.,Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine , University of Ottawa , Ottawa , Ontario K1H 8M5 , Canada
| | - Michel Gilbert
- National Research Council Canada , Human Health Therapeutics Research Centre , Ottawa , Ontario K1A 0R6 , Canada
| | - Simon Sauvé
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| | - Michel Girard
- Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , 251 Sir Frederick Banting , Tunney's Pasture, Ottawa , Ontario K1A 0K9 , Canada
| |
Collapse
|
25
|
Chen PL, Hu AYC, Lin CY, Weng TC, Lai CC, Tseng YF, Cheng MC, Chia MY, Lin WC, Yeh CT, Su IJ, Lee MS. Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness. Viruses 2019; 11:v11060543. [PMID: 31212631 PMCID: PMC6631248 DOI: 10.3390/v11060543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 06/04/2019] [Accepted: 06/05/2019] [Indexed: 11/23/2022] Open
Abstract
Novel low-pathogenic avian influenza (LPAI) H5N2 viruses hit poultry farms in Taiwan in 2003, and evolved into highly pathogenic avian influenza (HPAI) viruses in 2010. These viruses are reassortant viruses containing HA and NA genes from American-lineage H5N2 and six internal genes from local H6N1 viruses. According to a serological survey, the Taiwan H5N2 viruses can cause asymptomatic infections in poultry workers. Therefore, a development of influenza H5N2 vaccines is desirable for pandemic preparation. In this study, we employed reverse genetics to generate a vaccine virus having HA and NA genes from A/Chicken/CY/A2628/2012 (E7, LPAI) and six internal genes from a Vero cell-adapted high-growth H5N1 vaccine virus (Vero-15). The reassortant H5N2 vaccine virus, E7-V15, presented high-growth efficiency in Vero cells (512 HAU, 107.6 TCID50/mL), and passed all tests for qualification of candidate vaccine viruses. In ferret immunization, two doses of inactivated whole virus antigens (3 μg of HA protein) adjuvanted with alum could induce robust antibody response (HI titre 113.14). In conclusion, we have established reverse genetics to generate a qualified reassortant H5N2 vaccine virus for further development.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- Chlorocebus aethiops
- Ferrets
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Humans
- Influenza A Virus, H5N2 Subtype/genetics
- Influenza A Virus, H5N2 Subtype/growth & development
- Influenza A Virus, H5N2 Subtype/immunology
- Influenza A Virus, H5N2 Subtype/isolation & purification
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/genetics
- Influenza Vaccines/immunology
- Influenza Vaccines/isolation & purification
- Influenza, Human/prevention & control
- Neuraminidase/genetics
- Neuraminidase/immunology
- Reassortant Viruses/genetics
- Reassortant Viruses/growth & development
- Reassortant Viruses/immunology
- Reassortant Viruses/isolation & purification
- Reverse Genetics
- Taiwan
- Treatment Outcome
- Vaccines, Inactivated/administration & dosage
- Vaccines, Inactivated/immunology
- Vero Cells
- Viral Proteins/genetics
- Viral Proteins/immunology
Collapse
Affiliation(s)
- Po-Ling Chen
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
- Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan.
| | - Alan Yung-Chih Hu
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| | - Chun-Yang Lin
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| | - Tsai-Chuan Weng
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| | - Chia-Chun Lai
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
- College of Life Science, National Tsing Hua University, Hsinchu 30013, Taiwan.
| | - Yu-Fen Tseng
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| | - Ming-Chu Cheng
- Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.
- Animal Health Research Institutes, Danshui, New Taipei City 25158, Taiwan.
| | - Min-Yuan Chia
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
- Department of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan.
| | - Wen-Chin Lin
- Institute of Preventive Medicine, National Defence Medical Centre, Taipei 23742, Taiwan.
| | - Chia-Tsui Yeh
- Institute of Preventive Medicine, National Defence Medical Centre, Taipei 23742, Taiwan.
| | - Ih-Jen Su
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| | - Min-Shi Lee
- National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan.
| |
Collapse
|
26
|
Durous L, Julien T, Padey B, Traversier A, Rosa-Calatrava M, Blum LJ, Marquette CA, Petiot E. SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring. Vaccine 2019; 37:1614-1621. [DOI: 10.1016/j.vaccine.2019.01.083] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 01/15/2019] [Accepted: 01/28/2019] [Indexed: 12/19/2022]
|
27
|
Ramage W, Gaiotto T, Ball C, Risley P, Carnell GW, Temperton N, Cheung CY, Engelhardt OG, Hufton SE. Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin. Antibodies (Basel) 2019; 8:E14. [PMID: 31544820 PMCID: PMC6640691 DOI: 10.3390/antib8010014] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 01/30/2019] [Accepted: 02/01/2019] [Indexed: 11/23/2022] Open
Abstract
Influenza B virus (IBV) circulates in the human population and causes considerable disease burden worldwide, each year. Current IBV vaccines can struggle to mount an effective cross-reactive immune response, as strains become mismatched, due to constant antigenic changes. Additional strategies which use monoclonal antibodies, with broad reactivity, are of considerable interest, both, as diagnostics and as immunotherapeutics. Alternatives to conventional monoclonal antibodies, such as single domain antibodies (NanobodiesTM) with well-documented advantages for applications in infectious disease, have been emerging. In this study we have isolated single domain antibodies (sdAbs), specific to IBV, using alpacas immunised with recombinant hemagglutinin (HA) from two representative viruses, B/Florida/04/2006 (B/Yamagata lineage) and B/Brisbane/60/2008 (B/Victoria lineage). Using phage display, we have isolated a panel of single domain antibodies (sdAbs), with both cross-reactive and lineage-specific binding. Several sdAbs recognise whole virus antigens, corresponding to influenza B strains included in vaccines spanning over 20 years, and were capable of neutralising IBV pseudotypes corresponding to prototype strains from both lineages. Lineage-specific sdAbs recognised the head domain, whereas, sdAbs identified as cross-reactive could be classified as either head binding or stem binding. Using yeast display, we were able to correlate lineage specificity with naturally occurring sequence divergence, at residue 122 in the highly variable 120 loop of the HA1 domain. The single domain antibodies described, might have applications in IBV diagnostics, vaccine potency testing and as immunotherapeutics.
Collapse
Affiliation(s)
- Walter Ramage
- Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Tiziano Gaiotto
- Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Christina Ball
- Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Paul Risley
- Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - George W Carnell
- Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK.
| | - Nigel Temperton
- Infectious Diseases and Allergy Group, School of Pharmacy, University of Kent, Kent ME4 4TB, UK.
| | - Chung Y Cheung
- Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Othmar G Engelhardt
- Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Simon E Hufton
- Biotherapeutics Division, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| |
Collapse
|
28
|
VaxArray potency assay for rapid assessment of "pandemic" influenza vaccines. NPJ Vaccines 2018; 3:43. [PMID: 30323954 PMCID: PMC6175820 DOI: 10.1038/s41541-018-0080-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 08/01/2018] [Accepted: 08/10/2018] [Indexed: 11/08/2022] Open
Abstract
The VaxArray Influenza Pandemic HA (VXI-pHA) potency assay is a multiplexed sandwich immunoassay that consists of nine broadly reactive yet subtype-specific monoclonal capture antibodies printed in microarray format and a suite of fluor-labeled secondary antibodies that were selected to probe conserved HA epitopes. VXI-pHA was designed to optimize the probability that the ready-to-use assay would work for the most concerning, emergent influenza A strains, eliminating the need for the time-consuming process of reference reagents production. The performance of this new potency test was evaluated using a panel of 48 potentially pandemic strains of influenza viruses and vaccines spanning 16 years of antigenic drift, including the most recent pre-pandemic vaccine being developed against the "5th wave" A/H7N9 virus. The VXI-pHA assay demonstrated coverage of 93%, 92%, and 100% for H5, H7, and H9 antigens, respectively. The assay demonstrated high sensitivity with linear dynamic ranges of more than 150-fold and quantification limits ranging from 1 to 5 ng/mL. For three production lots of H7N9 monobulk drug substance, the assay exhibited excellent accuracy (100 ± 6%) and analytical precision (CV 6 ± 2%). The high assay sensitivity enabled robust detection and quantification of hemagglutinin in crude in-process samples and low-dose, adjuvanted vaccines with an accuracy of 100 ± 10%.
Collapse
|
29
|
Hebert CG, DiNardo N, Evans ZL, Hart SJ, Hachmann AB. Rapid quantification of vesicular stomatitis virus in Vero cells using Laser Force Cytology. Vaccine 2018; 36:6061-6069. [PMID: 30219365 DOI: 10.1016/j.vaccine.2018.09.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 08/24/2018] [Accepted: 09/01/2018] [Indexed: 01/06/2023]
Abstract
The ability to rapidly and accurately determine viral infectivity can help improve the speed of vaccine product development and manufacturing. Current methods to determine infectious viral titers, such as the end-point dilution (50% tissue culture infective dose, TCID50) and plaque assays are slow, labor intensive, and often subjective. In order to accelerate virus quantification, Laser Force Cytology (LFC) was used to monitor vesicular stomatitis virus (VSV) infection in Vero (African green monkey kidney) cells. LFC uses a combination of optical and fluidic forces to interrogate single cells without the use of labels or antibodies. Using a combination of variables measured by the Radiance™ LFC instrument (LumaCyte), an infection metric was developed that correlates well with the viral titer as measured by TCID50 and shortens the timeframe from infection to titer determination from 3 days to 16 h (a 4.5 fold reduction). A correlation was also developed between in-process cellular measurements and the viral titer of collected supernatant, demonstrating the potential for real-time infectivity measurements. Overall, these results demonstrate the utility of LFC as a tool for rapid infectivity measurements throughout the vaccine development process.
Collapse
Affiliation(s)
- Colin G Hebert
- LumaCyte, LLC, 1145 River Road, Suite 16, Charlottesville, VA 22901, USA
| | - Nicole DiNardo
- Thermo Fisher Scientific, Inc., 3175 Staley Road, Grand Island, NY 14072, USA
| | - Zachary L Evans
- LumaCyte, LLC, 1145 River Road, Suite 16, Charlottesville, VA 22901, USA
| | - Sean J Hart
- LumaCyte, LLC, 1145 River Road, Suite 16, Charlottesville, VA 22901, USA
| | | |
Collapse
|
30
|
Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination. Vaccine 2018; 36:6144-6151. [PMID: 30194004 DOI: 10.1016/j.vaccine.2018.08.065] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2018] [Revised: 08/09/2018] [Accepted: 08/26/2018] [Indexed: 12/23/2022]
Abstract
Influenza vaccines are the most effective intervention to prevent the substantial public health burden of seasonal and pandemic influenza. Hemagglutinin (HA), as the main antigen in inactivated influenza vaccines (IIVs), elicits functional neutralizing antibodies and largely determines IIV effectiveness. HA potency has been evaluated by single-radial immunodiffusion (SRID), the standard in vitro potency assay for IIVs, to predict vaccine immunogenicity with a correlation to protective efficacy. We previously reported that limited trypsin digestion (LTD) selectively degraded stressed HA, so that an otherwise conformationally insensitive biophysical quantification technique could specifically quantify trypsin-resistant, immunologically active HA. Here, we demonstrate that isotope dilution mass spectrometry (IDMS), a method capable of quantifying the absolute HA concentration without reference antigen use, can be further expanded by adding LTD followed with precipitation to selectively quantify the active HA. We test the LTD-IDMS assay on H7N9 vaccines stressed by low pH, raised temperature, or freeze/thaw cycles. This method, unlike SRID, has no requirement for strain-specific reference antigens or antibodies and can generate potency values that correlate with SRID. Thus, LTD-IDMS is a promising alternative in vitro potency assay for influenza vaccines to complement and potentially replace SRID in a pandemic when strain specific reagents may not be readily available.
Collapse
|
31
|
Aly SE, Hussein HA, Aly¹ AHM, Abdel-Baky MH, El-Sanousi AA. Assessment of in vitro potency of inactivated Newcastle disease oil-adjuvanted vaccines using hemagglutination test and blocking ELISA. Vet World 2018; 11:1222-1228. [PMID: 30410225 PMCID: PMC6200565 DOI: 10.14202/vetworld.2018.1222-1228] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 07/20/2018] [Indexed: 11/20/2022] Open
Abstract
AIM The present study was aimed to establish a protocol for the evaluation of the in vitro potency of commercial inactivated Newcastle disease virus (NDV) oil-adjuvanted vaccines using hemagglutination test (HA) and blocking ELISA (B-ELISA) based on polyclonal antibodies. MATERIALS AND METHODS Aqueous phases from a total of 47 batches of inactivated NDV vaccines manufactured by 20 different companies were extracted with isopropyl myristate. The viral antigen in each sample was detected and quantified by a standard HA test and a B-ELISA assay. To verify the efficiency of the antigen extraction method used in the batches which showed HA and to test the validity of using in vitro antigen quantification by HA and B-ELISA tests, a subset of 13 batches (selected from the total 47 batches) was inoculated in groups of 3-4-week-old specific pathogen-free chickens using the recommended vaccine dose. The immunogenicity of the selected vaccine batches was assessed by the NDV-hemagglutination inhibition antibody titers in individual serum samples collected 4 weeks after vaccination. Further, the efficacy of the vaccines and their protection rates were determined by a challenge test carried out for the vaccinated chickens with the Egyptian 2012 isolate of the virulent NDV genotype VII. RESULTS A strong correlation was observed between HA titers and B-ELISA mean titers in the tested 47 batches (R2=0.817). This indicated the possibility of using the latter in vitro assays for vaccine potency assessment. The recommended protective NDV antigen titer measured by B-ELISA was determined to be 28 ELISA units per dose. The comparison between the HA titers of the aqueous extracts of test vaccines and the corresponding results of in vivo potency assays (i.e., immunogenicity and efficacy), including antibody titers in the serum of vaccinated birds, indicated that the efficiency of the antigen extraction used may interfere with obtaining a strong correlation between the in vitro and in vivo results. CONCLUSION HA or B-ELISA tests can be used as rapid and cost-effective alternatives to traditional in vivo potency tests for vaccine potency assessment by quantifying the NDV antigen present in aqueous phase extracts of the tested vaccines. The latter in vitro protocol, however, requires efficient extraction of the antigen to be able to obtain good correlation with the traditional in vivo potency tests.
Collapse
Affiliation(s)
- Saleh E. Aly
- Central Laboratory for Evaluation of Veterinary Biologics, Abbasia 11381, Egypt
| | - Hussein Ali Hussein
- Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt
| | - Abdel-Hakim M. Aly¹
- Central Laboratory for Evaluation of Veterinary Biologics, Abbasia 11381, Egypt
| | | | - Ahmed A. El-Sanousi
- Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt
| |
Collapse
|
32
|
Quantitative ELISA sandwich for a new vaccine against avian influenza virus H5N1. J Immunol Methods 2018; 459:70-75. [PMID: 29803776 DOI: 10.1016/j.jim.2018.05.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 03/21/2018] [Accepted: 05/09/2018] [Indexed: 11/23/2022]
Abstract
Analytical techniques are essential in the process of standardizing and validating vaccines. In this study we described a methodology to establish an ELISA sandwich for the quantification of a new vaccine against avian influenza virus H5N1 based on the main antigenic determinant of the virus, the extracellular domain of the glycoprotein hemagglutinin (HA), fused to the extracellular domain of the chicken CD154 glycoprotein (HACD). The chimerical proteins HA and HACD were produced in SiHa cells and the experiments were performed by using three monoclonal antibodies (MAb-HA1, MAb-HA2 and MAb-HA3), alone or conjugated to horseradish peroxidase (HRP-HA1, HRP-HA2 and HRP-HA3). The hemagglutination inhibition assay was carried out with a negative and a positive H5N2 reference serum, together with the antigen H5N1 A/Mallard/Italy/3401/05, all purchased from the "Istituto Zooprofilattico delle Venezie", Italy. After demonstrating the similar recognition pattern between the HA and the HACD proteins, the MAb-HA2 at a concentration of 2,5 μg/mL was selected as the capture antibody and the HRP-HA3 at a dilution of 1/20000 was selected as the detection antibody due to their optimal values of optical density at these conditions. The best dynamic range of the standard curve using the protein HACD was achieved at concentrations from 100 to 1,56 ng/mL. There were no significant differences when five batches of HACD were quantified by the ELISA sandwich and the bicinchoninic acid method linked to densitometry. In conclusion, the final parameters for the quantification of the chimeric protein HACD using an ELISA sandwich were described, which could contribute to develop a large-scale process for the final vaccine production.
Collapse
|
33
|
Wen Y, Palladino G, Xie Y, Ferrari A, Settembre EC. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Vaccine 2018; 36:3010-3017. [PMID: 29680201 DOI: 10.1016/j.vaccine.2018.04.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 03/29/2018] [Accepted: 04/09/2018] [Indexed: 12/14/2022]
Abstract
Influenza vaccines are the most effective intervention to prevent the substantial public health burden of seasonal and pandemic influenza. The capability of hemagglutinin (HA), the main antigen in inactivated influenza vaccines (IIVs), to elicit functional neutralizing antibodies determines IIV effectiveness. When HA is subjected to environmental stress during manufacturing or while stored prior to administration, such as low pH and temperature excursions, the HA immunological activity can be affected. Single-radial immunodiffusion (SRID), the standard in vitro potency assay for IIVs, is believed to specifically detect immunologically active HA and has been applied to evaluate HA stability against stress. Here we report that transient low pH treatment and freeze/thaw cycles with HA in PBS abolish SRID-quantified in vitro potency for all HAs of multiple influenza strains. Raised temperature substantially decreases in vitro potency with more extensive HA structural changes. Chemical stress and mechanical stress moderately change SRID in vitro potency values in a strain-dependent manner. Trypsin digestion, which selectively degrades stressed HA, followed by RP-HPLC quantification as a candidate alternative in vitro potency assay yields results comparable to SRID. Mouse immunogenicity studies confirm that HA stressed by transient low pH treatment does not elicit functional antibodies in vivo, nor does it have a measureable SRID value. However, HA stressed by raised temperature elicits high titers of functional antibodies in vivo despite substantial loss of SRID in vitro potency. This discrepancy between SRID in vitro potency and vaccine immunogenicity suggests that SRID may not reliably indicate IIV potency under all conditions. Further efforts to develop alternate potency assays that can better predict in vivo immunogenicity should continue along with additional studies exploring HA conformation, SRID values and consequent immunogenicity.
Collapse
Affiliation(s)
- Yingxia Wen
- Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA.
| | | | - Yuhong Xie
- Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA
| | - Annette Ferrari
- Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA
| | - Ethan C Settembre
- Seqirus, A CSL Company, 50 Hampshire Street, Cambridge, MA 02139, USA
| |
Collapse
|
34
|
Kuck LR, Byrne-Nash R, Gillis J, Bueter K, Couzens LK, Eichelberger MC, Rowlen KL. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines. Vaccine 2018; 36:2937-2945. [PMID: 29699789 DOI: 10.1016/j.vaccine.2018.04.048] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 04/13/2018] [Accepted: 04/17/2018] [Indexed: 01/14/2023]
Abstract
Practical methods to measure the potency of influenza vaccines are needed as alternatives for the standard single radial immunodiffusion (SRID) assay. VaxArray assays for influenza hemagglutinin (HA) and neuraminidase (NA) have been developed to address this need. In this report, we evaluate the use of these assays to assess the potency of HA and NA of an A/H3N2 subunit vaccine by determining the correlation between the amounts measured by VaxArray and the immunogenicity in mice. The antibody response after one and two doses of five formulations of the vaccine ranging from 5 µg/mL to 80 µg/mL of HA, was measured by hemagglutination inhibition (HAI) and neuraminidase inhibition (NAI) assays. For hemagglutinin, vaccine potency determined by VaxArray was equivalent to potency measured SRID and these amounts were predictive of immunogenicity, with excellent correlation between potency measured by VaxArray and the HAI geometric mean titers (GMT). Likewise, the amount of NA measured by VaxArray was predictive of the NAI GMT. The VaxArray NA assay reported non-detectable levels of intact NA for a sample that had been heat degraded at 56 °C for 20 h, demonstrating that the assay measures the native, active form of NA. Similarly, the HA potency measured by VaxArray in this heat-treated sample was very low when a monoclonal antibody was used to detect the amount of antigen bound. Importantly, the force degraded sample induced low HAI titers and the NAI titers were not measurable, supporting the conclusion that the VaxArray HA and NA assays measure the immunogenic forms of these A/H3N2 antigens. This study indicates that VaxArray assays can be used to assess the potency of HA and NA components in influenza vaccines as a proxy for immunogenicity.
Collapse
Affiliation(s)
- Laura R Kuck
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Rose Byrne-Nash
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Jacob Gillis
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Katie Bueter
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Laura K Couzens
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Maryna C Eichelberger
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Kathy L Rowlen
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States.
| |
Collapse
|
35
|
Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F. An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS One 2018; 13:e0194830. [PMID: 29617394 PMCID: PMC5884525 DOI: 10.1371/journal.pone.0194830] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 03/09/2018] [Indexed: 11/29/2022] Open
Abstract
The standard method to quantify the hemagglutinin content of influenza virus vaccines is the single radial immunodiffusion assay. This assay primarily relies on polyclonal antibodies against the head domain of the influenza virus hemagglutinin, which is the main target antigen of influenza virus vaccines. Novel influenza virus vaccine candidates that redirect the immune response towards the evolutionary more conserved hemagglutinin stalk, including chimeric hemagglutinin and headless hemagglutinin constructs, are highly dependent on the structural integrity of the protein to present conformational epitopes for neutralizing antibodies. In this study, we describe a novel enzyme-linked immunosorbent assay that allows quantifying the amount of hemagglutinin with correctly folded stalk domains and which could be further developed into a potency assay for stalk-based influenza virus vaccines.
Collapse
Affiliation(s)
- Madhusudan Rajendran
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Weina Sun
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Phillip Comella
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Raffael Nachbagauer
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Teddy John Wohlbold
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Fatima Amanat
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Ericka Kirkpatrick
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Peter Palese
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Florian Krammer
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- * E-mail:
| |
Collapse
|
36
|
Wood JM, Weir JP. Standardisation of inactivated influenza vaccines-Learning from history. Influenza Other Respir Viruses 2018; 12:195-201. [PMID: 29356318 PMCID: PMC5820418 DOI: 10.1111/irv.12543] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/11/2018] [Indexed: 01/15/2023] Open
Abstract
The single radial immunodiffusion assay has been the accepted method for determining the potency of inactivated influenza vaccines since 1978. The worldwide adoption of this assay for vaccine standardisation was facilitated through collaborative studies that demonstrated a high level of reproducibility and its applicability to the different types of influenza vaccine being produced at that time. Clinical evidence indicated the relevance of SRID as a potency assay. Unique features of the SRID assay are likely responsible for its longevity even as newer technologies for vaccine characterisation have been developed and refined. Nevertheless, there are significant limitations to the SRID assay that indicate the need for improvement, and there has been a substantial amount of work undertaken in recent years to develop and evaluate alternative potency assays, including collaborative studies involving research laboratories, regulatory agencies and vaccine manufacturers. Here, we provide an overview of the history of inactivated influenza vaccine potency testing, the current state of alternative assay development and the some of the major challenges to be overcome before implementation of new assays for potency determination.
Collapse
Affiliation(s)
- John M Wood
- Formerly National Institute for Biological Standards and Control, Potters Bar, Bushey, Herts, UK
| | - Jerry P Weir
- Division of Viral Products, Center for Biologics Evaluations and Research, Food and Drug Administration, Silver Spring, MD, USA
| |
Collapse
|
37
|
Abstract
Compared with biologics, vaccine potency assays represent a special challenge due to their unique compositions, multivalency, long life cycles and global distribution. Historically, vaccines were released using in vivo potency assays requiring immunization of dozens of animals. Modern vaccines use a variety of newer analytical tools including biochemical, cell-based and immunochemical methods to measure potency. The choice of analytics largely depends on the mechanism of action and ability to ensure lot-to-lot consistency. Live vaccines often require cell-based assays to ensure infectivity, whereas recombinant vaccine potency can be reliably monitored with immunoassays. Several case studies are presented to demonstrate the relationship between mechanism of action and potency assay. A high-level decision tree is presented to assist with assay selection.
Collapse
|
38
|
Buffin S, Ikhelef N, Prudent J, Dubayle J, Nougarede N, Varenne MP, Moste C, Legastelois I. A latex agglutination assay to quantify the amount of hemagglutinin protein in adjuvanted low-dose influenza monovalent vaccines. J Virol Methods 2018; 251:46-53. [PMID: 29030070 DOI: 10.1016/j.jviromet.2017.10.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 10/06/2017] [Accepted: 10/10/2017] [Indexed: 12/29/2022]
Abstract
To formulate inactivated influenza vaccines, the concentration of hemagglutinin (HA) must be accurately determined. The standard test currently used to measure HA in influenza vaccines is the Single Radial Immunodiffusion (SRID) assay. We developed a very rapid, simple and sensitive alternative quantitative HA assay, namely the Latex Agglutination Assay (LAA). The LAA uses the Spherotest® technology, which is based on the agglutination of HA-specific immunoglobulin-coated latex beads. The amount of HA in a sample is calculated from the level of bead agglutination by a simple absorbance measurement at 405nm against a standard curve generated using a monovalent vaccine standard. In less than 2hours, tens of samples could be quantified using the LAA as opposed to 2days for the SRID assay. Ten steps are required to complete an SRID assay as compared to 6 steps for the LAA, from sample preparation through spectrophotometric analysis. Furthermore, the limit of detection of the LAA was found to be approximately 15ng HA/mL, similar to an ELISA, with the quantification of less than 1.8μg HA/mL. The quantification limit of the SRID is usually considered to be approximately 5μg HA/mL. The development of the assay and a comparison of the titers obtained by SRID and LAA for several monovalent vaccines corresponding to various strains were performed. For A/H5N1 and A/H1N1 monovalent vaccines, the LAA was found to be linear and accurate as compared to the SRID. The precision of the LAA was close to that of the standard test, and good reproducibility from one laboratory to another was observed. Moreover, the LAA enabled HA quantification in AlOOH-adjuvanted and in emulsion-adjuvanted low-dose vaccines as well as unadjuvanted vaccines. In conclusion, LAA may be useful to rapidly and accurately measure influenza HA protein in monovalent vaccines, especially in those containing less than 5μg/mL of HA in the presence of an adjuvant.
Collapse
Affiliation(s)
- Sophie Buffin
- Research and Development, Sanofi Pasteur, Marcy L'Etoile, France.
| | | | - Julien Prudent
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, United Kingdom
| | - Joseline Dubayle
- Research and Development, Sanofi Pasteur, Marcy L'Etoile, France
| | | | | | - Catherine Moste
- Research and Development, Sanofi Pasteur, Marcy L'Etoile, France
| | | |
Collapse
|
39
|
Vasudevan A, Woerner A, Schmeisser F, Verma S, Williams O, Weir JP. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays. Influenza Other Respir Viruses 2017; 12:250-258. [PMID: 29152878 PMCID: PMC5820428 DOI: 10.1111/irv.12528] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/13/2017] [Indexed: 01/28/2023] Open
Abstract
Background The single radial immunodiffusion (SRID) assay, the accepted method for determining potency of inactivated influenza vaccines, measures an immunogenic form of the influenza hemagglutinin. Nevertheless, alternative methods for measuring vaccine potency have been explored to address some of the weaknesses of the SRID assay, including limited sensitivity and the requirement for large amounts of standardized reagents. Monoclonal antibody (mAb)‐based potency assays also have the ability to detect and measure relevant immunogenic forms of HA. Objectives The objective of this study was to continue evaluation of mAb‐based alternative methods for measuring the potency of inactivated influenza vaccines, focusing on A(H7N9) pandemic influenza vaccines. Methods Several murine mAbs that recognize different epitopes on the H7 hemagglutinin (HA) were identified and characterized. These mAbs were evaluated in both a mAb‐capture ELISA and a mAb‐based biolayer interferometry (BLI) assay. Results Results indicated that potency of inactivated A(H7N9) vaccines, including vaccine samples that were stressed by heat treatment, measured by either alternative method correlated well with potency determined by the traditional SRID potency assay. Conclusions The availability of multiple H7 mAbs, directed to different HA epitopes, provides needed redundancy in the potency analysis as A(H7N9) viruses continue to evolve antigenically and suggests the importance of having a broad, well‐characterized panel of mAbs available for development of vaccines against influenza strains with pandemic potential. In addition, the results highlight the potential of mAb‐based platform such as ELISA and BLI for development as alternative methods for determining the potency of inactivated influenza vaccines.
Collapse
Affiliation(s)
- Anupama Vasudevan
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Amy Woerner
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Falko Schmeisser
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Swati Verma
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Ollie Williams
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| | - Jerry P Weir
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
| |
Collapse
|
40
|
Lorbetskie B, Fortin N, Durno L, Wang J, Li C, Li X, Girard M, Sauvé S. Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method. J Chromatogr A 2017; 1528:18-24. [DOI: 10.1016/j.chroma.2017.10.041] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 10/13/2017] [Accepted: 10/16/2017] [Indexed: 01/14/2023]
|
41
|
Choi Y, Lee S, Kwon SY, Lee Y, Park YK, Ban SJ. Analysis of the proficiency of single radial immunodiffusion assays for quality control of influenza vaccines in Korea. Biologicals 2017; 50:137-140. [PMID: 29111376 DOI: 10.1016/j.biologicals.2017.08.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Revised: 07/28/2017] [Accepted: 08/01/2017] [Indexed: 11/17/2022] Open
Abstract
Influenza vaccine potency, which is determined by quantitatively measuring the content of Hemagglutinin (HA), is an essential index representing the efficacy of the vaccine. Standardization of the single radial immunodiffusion (SRID) assay, a method for measuring HA content, and proficiency of the testing institutions are crucial for influenza vaccine quality control. Herein, we assessed the proficiency of SRID assays at the National Control Laboratory (NCL) of Korea and several vaccine manufacturers. Eight laboratories participated in this study, and the proficiencies of all laboratories yielded satisfactory results in overall SRID assays. In contrast, there were some unsatisfactory results in measuring with different types of agarose gel plates produced by other laboratories. Overall, our findings demonstrated that the proficiency of SRID assay in the tested laboratories is acceptable for quality control of influenza vaccines and that detailed review on the validation reports regarding the test methods will be helpful for better control.
Collapse
Affiliation(s)
- Yejin Choi
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju 28159, Republic of Korea; Department of Biochemistry, College of Natural Science, Chungbuk National University, Cheongju 28644, Republic of Korea
| | - Sunmi Lee
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju 28159, Republic of Korea; School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
| | - Seong Yi Kwon
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju 28159, Republic of Korea
| | - Younghee Lee
- Department of Biochemistry, College of Natural Science, Chungbuk National University, Cheongju 28644, Republic of Korea
| | - Yong Keun Park
- School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
| | - Sang Ja Ban
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju 28159, Republic of Korea.
| |
Collapse
|
42
|
Merani S, Pawelec G, Kuchel GA, McElhaney JE. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Front Immunol 2017; 8:784. [PMID: 28769922 PMCID: PMC5512344 DOI: 10.3389/fimmu.2017.00784] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2017] [Accepted: 06/21/2017] [Indexed: 12/13/2022] Open
Abstract
The number of people over the age of 60 is expected to double by 2050 according to the WHO. This emphasizes the need to ensure optimized resilience to health stressors in late life. In older adults, influenza is one of the leading causes of catastrophic disability (defined as the loss of independence in daily living and self-care activities). Influenza vaccination is generally perceived to be less protective in older adults, with some studies suggesting that the humoral immune response to the vaccine is further impaired in cytomegalovirus (CMV)-seropositive older people. CMV is a β-herpes virus infection that is generally asymptomatic in healthy individuals. The majority of older adults possess serum antibodies against the virus indicating latent infection. Age-related changes in T-cell-mediated immunity are augmented by CMV infection and may be associated with more serious complications of influenza infection. This review focuses on the impact of aging and CMV on immune cell function, the response to influenza infection and vaccination, and how the current understanding of aging and CMV can be used to design a more effective influenza vaccine for older adults. It is anticipated that efforts in this field will address the public health need for improved protection against influenza in older adults, particularly with regard to the serious complications leading to loss of independence.
Collapse
Affiliation(s)
- Shahzma Merani
- Health Sciences North Research Institute, Sudbury, ON, Canada
| | - Graham Pawelec
- Health Sciences North Research Institute, Sudbury, ON, Canada.,Second Department of Internal Medicine, University of Tübingen Medical Center, Tübingen, Germany
| | - George A Kuchel
- UConn Center on Aging, UConn Health, Farmington, CT, United States
| | | |
Collapse
|
43
|
Choi Y, Kwon SY, Oh HJ, Shim S, Chang S, Chung HJ, Kim DK, Park Y, Lee Y. Application of recombinant hemagglutinin proteins as alternative antigen standards for pandemic influenza vaccines. Biotechnol Lett 2017; 39:1375-1380. [PMID: 28612264 DOI: 10.1007/s10529-017-2372-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2017] [Accepted: 05/26/2017] [Indexed: 11/27/2022]
Abstract
OBJECTIVES The single radial immunodiffusion (SRID) assay, used to quantify hemagglutinin (HA) in influenza vaccines, requires reference reagents; however, because centralized production of reference reagents may slow the emergency deployment of vaccines, alternatives are needed. RESULTS We investigated the production of HA proteins using recombinant DNA technology, rather than a traditional egg-based production process. The HA proteins were then used in an SRID assay as a reference antigen. We found that HA can be quantified in both egg-based and cell-based influenza vaccines when recombinant HAs (rHAs) are used as the reference antigen. Furthermore, we confirmed that rHAs obtained from strains with pandemic potential, such as H5N1, H7N3, H7N9, and H9N2 strains, can be utilized in the SRID assay. The rHA production process takes just one month, in contrast to the traditional process that takes three to four months. CONCLUSIONS The use of rHAs may reduce the time required to produce reference reagents and facilitate timely introduction of vaccines during emergencies.
Collapse
Affiliation(s)
- Yejin Choi
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
- Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju-si, Chungcheongbuk-do, 28644, Republic of Korea
| | - Seong Yi Kwon
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Ho Jung Oh
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea.
| | - Sunbo Shim
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Seokkee Chang
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Hye Joo Chung
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Do Keun Kim
- Biologics Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Younsang Park
- Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea
| | - Younghee Lee
- Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju-si, Chungcheongbuk-do, 28644, Republic of Korea
| |
Collapse
|
44
|
Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, Weiss CD, Weir JP. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. PLoS One 2017; 12:e0175733. [PMID: 28423025 PMCID: PMC5396888 DOI: 10.1371/journal.pone.0175733] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 03/30/2017] [Indexed: 12/12/2022] Open
Abstract
Co-circulation of two antigenically and genetically distinct lineages of influenza B virus, represented by prototype viruses B/Victoria/2/1987 and B/Yamagata/16/1988, has led to the development of quadrivalent influenza vaccines that contain two influenza B antigens. The inclusion of two influenza B antigens presents challenges for the production and regulation of inactivated quadrivalent vaccines, including the potential for cross-reactivity of the reagents used in identity and potency assays because of the relative close relatedness of the hemagglutinin (HA) from the two virus lineages. Monoclonal antibodies (mAbs) specific for the two lineages of influenza B HA were generated and characterized and used to set-up simple identity tests that distinguish the influenza B antigens in inactivated trivalent and quadrivalent vaccines. The lineage-specific mAbs bound well to the HA of influenza B strains included in influenza vaccines over a period of more than 10 years, suggesting that identity tests using such lineage-specific mAbs would not necessarily have to be updated with every influenza B vaccine strain change. These lineage-specific mAbs were also used in an antibody capture ELISA format to quantify HA in vaccine samples, including monovalent, trivalent, and quadrivalent vaccine samples from various manufacturers. The results demonstrated correlation with HA values determined by the traditional single radial immunodiffusion (SRID) assay. Further, the antibody-capture ELISA was able to distinguish heat-stressed vaccine from unstressed vaccine, and was similar to the SRID in quantifying the resultant loss of potency. These mAb reagents should be useful for further development of antibody-based alternative influenza B identity and potency assays.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/biosynthesis
- Antibodies, Monoclonal/chemistry
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/chemistry
- Antigens, Viral/chemistry
- Antigens, Viral/immunology
- Chickens
- Dogs
- Enzyme-Linked Immunosorbent Assay/methods
- Hemagglutination Inhibition Tests
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Hemagglutinin Glycoproteins, Influenza Virus/metabolism
- Humans
- Immunodiffusion/methods
- Immunogenicity, Vaccine
- Influenza B virus/immunology
- Influenza B virus/isolation & purification
- Influenza Vaccines/analysis
- Influenza Vaccines/biosynthesis
- Influenza Vaccines/immunology
- Influenza, Human/prevention & control
- Madin Darby Canine Kidney Cells
- Mice
- Protein Binding
- Vaccines, Inactivated
- Vaccines, Subunit
- Zygote/virology
Collapse
Affiliation(s)
- Swati Verma
- Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Jackeline Soto
- Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Anupama Vasudevan
- Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Falko Schmeisser
- Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Esmeralda Alvarado-Facundo
- Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Wei Wang
- Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Carol D. Weiss
- Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
| | - Jerry P. Weir
- Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America
- * E-mail:
| |
Collapse
|
45
|
Wan H, Sultana I, Couzens LK, Mindaye S, Eichelberger MC. Assessment of influenza A neuraminidase (subtype N1) potency by ELISA. J Virol Methods 2017; 244:23-28. [PMID: 28257802 DOI: 10.1016/j.jviromet.2017.02.015] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 02/16/2017] [Indexed: 11/18/2022]
Abstract
Antibodies that inhibit neuraminidase (NA) activity of influenza virus provide resistance against disease and have been associated with milder epidemics. Although studies have demonstrated a correlation between NA inhibition antibody titers and vaccine efficacy, neither the quantity nor form of NA is measured in seasonal and pandemic influenza vaccines. In this report, we describe development of enzyme-linked immunosorbent assays (ELISAs) that are suitable for quantitation of the native form of NA of subtype N1. The assays use mouse monoclonal antibodies (mAbs) 1H5 and CD6 to capture NAs of viruses, and a different mAb 4E9 to detect bound antigen. The 1H5-capture ELISA detects NAs of seasonal and pandemic H1N1 viruses as well as H5N1 viruses and has a limit of quantitation (LOQ) of 5.5ng/mL for seasonal H1N1A/Brisbane/59/2007 NA. The CD6-capture ELISA is specific for NA of the 2009 pandemic viruses with a LOQ of 67ng/mL for A/California/07/2009 NA. The ELISA signals in both assays are proportional to NA enzymatic activity and correlate with NA immunogenicity. The ELISAs we describe may expedite the development of NA-based influenza vaccines by providing a practical assay to measure NA potency.
Collapse
Affiliation(s)
- Hongquan Wan
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Ishrat Sultana
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Laura K Couzens
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Samuel Mindaye
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States
| | - Maryna C Eichelberger
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States.
| |
Collapse
|
46
|
Kuck LR, Saye S, Loob S, Roth-Eichhorn S, Byrne-Nash R, Rowlen KL. VaxArray assessment of influenza split vaccine potency and stability. Vaccine 2017; 35:1918-1925. [PMID: 28262335 DOI: 10.1016/j.vaccine.2017.02.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 01/27/2017] [Accepted: 02/14/2017] [Indexed: 12/12/2022]
Abstract
Vaccine manufacturers require more rapid and accurate tools to characterize the potency and stability of their products. Currently, the gold standard for influenza vaccine potency is the single radial immunodiffusion (SRD) assay, which has inherent disadvantages. The primary objective of this study was to investigate the ability of the VaxArray Influenza (VXI) seasonal hemagglutinin (sHA) potency assay to accurately quantify potency and stability in finished vaccines as well as to quantify hemagglutinin protein (HA) within crude in-process samples. Monobulk intermediates and mono- and multivalent vaccines were tested using VXI. Quantification of HA in crude samples was evaluated by spiking known concentrations of HA into allantoic fluid. VXI generated SRD equivalent potency measurements with high accuracy (within ±10%) and precision (CV 10±4%) for antigen components of monobulk intermediates and multivalent split vaccines. For these vaccines and vaccine intermediates, the VXI linear dynamic range was ∼0.01-0.6μg/mL, which is 12× greater than the linear range of SRD. The measured sample limit of detection (LOD) for VXI varied from 0.005 to 0.01μg/mL for the different subtypes, which in general is ≥600× lower than the LOD for SRD. VXI was able to quantify HA in crude samples where HA only accounts for 0.02% of the total protein content. Stability indication was investigated by tracking measured potency as a function of time at elevated temperature by both SRD and VXI. After 20 h at 56°C, the ratio of VXI to SRD measured potency in a quadrivalent vaccine was 76%, 125%, 60%, and 98% for H1/California, H3/Switzerland, B/Phuket and B/Brisbane, respectively. Based on the study results, it is concluded that VXI is a rapid, multiplexed immunoassay that can be used to accurately determine flu vaccine potency and stability in finished product and in crude samples from upstream processes.
Collapse
Affiliation(s)
- Laura R Kuck
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States.
| | - Stephen Saye
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Sam Loob
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Sylke Roth-Eichhorn
- GlaxoSmithKline Biologicals, NL der SB Pharma GmbH & Co. KG, Zirkusstraße 40, 01069 Dresden, Germany
| | - Rose Byrne-Nash
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States
| | - Kathy L Rowlen
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, United States.
| |
Collapse
|
47
|
Gaiotto T, Hufton SE. Cross-Neutralising Nanobodies Bind to a Conserved Pocket in the Hemagglutinin Stem Region Identified Using Yeast Display and Deep Mutational Scanning. PLoS One 2016; 11:e0164296. [PMID: 27741319 PMCID: PMC5065140 DOI: 10.1371/journal.pone.0164296] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 09/22/2016] [Indexed: 12/20/2022] Open
Abstract
Cross-neutralising monoclonal antibodies against influenza hemagglutinin (HA) are of considerable interest as both therapeutics and diagnostic tools. We have recently described five different single domain antibodies (nanobodies) which share this cross-neutralising activity and suggest their small size, high stability, and cleft binding properties may present distinct advantages over equivalent conventional antibodies. We have used yeast display in combination with deep mutational scanning to give residue level resolution of positions in the antibody-HA interface which are crucial for binding. In addition, we have mapped positions within HA predicted to have minimal effect on antibody binding when mutated. Our cross-neutralising nanobodies were shown to bind to a highly conserved pocket in the HA2 domain of A(H1N1)pdm09 influenza virus overlapping with the fusion peptide suggesting their mechanism of action is through the inhibition of viral membrane fusion. We also note that the epitope overlaps with that of CR6261 and F10 which are human monoclonal antibodies in clinical development as immunotherapeutics. Although all five nanobodies mapped to the same highly conserved binding pocket we observed differences in the size of the epitope footprint which has implications in comparing the relative genetic barrier each nanobody presents to a rapidly evolving influenza virus. To further refine our epitope map, we have re-created naturally occurring mutations within this HA stem epitope and tested their effect on binding using yeast display. We have shown that a D46N mutation in the HA2 stem domain uniquely interferes with binding of R2b-E8. Further testing of this substitution in the context of full length purified HA from 1918 H1N1 pandemic (Spanish flu), 2009 H1N1 pandemic (swine flu) and highly pathogenic avian influenza H5N1 demonstrated binding which correlated with D46 whereas binding to seasonal H1N1 strains carrying N46 was absent. In addition, our deep sequence analysis predicted that binding to the emerging H1N1 strain (A/Christchurch/16/2010) carrying the HA2-E47K mutation would not affect binding was confirmed experimentally. This demonstrates yeast display, in combination with deep sequencing, may be able to predict antibody reactivity to emerging influenza strains so assisting in the preparation for future influenza pandemics.
Collapse
Affiliation(s)
- Tiziano Gaiotto
- Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, United Kingdom
| | - Simon E. Hufton
- Biotherapeutics Group, National Institute for Biological Standards and Control, a centre of the Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, United Kingdom
- * E-mail:
| |
Collapse
|
48
|
Wen Y, Palladino G, Xie Y, Ferrari A, Ma X, Han L, Dormitzer PR, Settembre EC. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings. Vaccine 2016; 34:3388-95. [PMID: 27154389 DOI: 10.1016/j.vaccine.2016.04.091] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2016] [Revised: 04/25/2016] [Accepted: 04/26/2016] [Indexed: 10/21/2022]
Abstract
Influenza vaccines are the primary intervention to prevent the substantial health burden of seasonal and pandemic influenza. Subunit and split influenza vaccines are formulated, released for clinical use, and tested for stability based on their content of immunologically active (capable of eliciting functional antibodies) hemagglutinin (HA). Single-radial immunodiffusion (SRID), the standard in vitro potency assay in the field, is believed to specifically detect immunologically active HA. We confirmed that, with conformationally homogeneous HA preparations, SRID specifically detected native, pre-fusion HA, which elicited influenza neutralizing and hemagglutination inhibiting (HI) antibodies in mice, and it did not detect low-pH stressed, post-fusion HA, which was selectively removed from the SRID gel during a blotting step and was significantly less immunologically active. This selective detection was due to the SRID format, not a conformational specificity of the sheep antiserum used in the SRID, as the same antiserum detected non-stressed and low-pH stressed HA similarly when used in an ELISA format. However, when low-pH stressed HA was mixed with non-stressed HA, SRID detected both forms in mixed immunoprecipitin rings, leading to over-quantification of pre-fusion HA. We previously reported that trypsin digestion of antigen samples selectively degrade stressed HA, so that an otherwise conformationally insensitive biophysical quantification technique, reversed-phase high pressure liquid chromatography (RP-HPLC), can specifically quantify trypsin-resistant, immunologically active, pre-fusion HA. Here, we report that trypsin digestion can also improve the specificity of SRID so that it can quantify immunologically active, pre-fusion HA when it is mixed with less immunologically active, post-fusion HA.
Collapse
Affiliation(s)
- Yingxia Wen
- Seqirus, A CSL Company, 45 Sidney Street, Cambridge, MA 02139, USA
| | | | - Yuhong Xie
- Seqirus, A CSL Company, 45 Sidney Street, Cambridge, MA 02139, USA
| | - Annette Ferrari
- Seqirus, A CSL Company, 45 Sidney Street, Cambridge, MA 02139, USA
| | - Xiuwen Ma
- Seqirus, A CSL Company, 45 Sidney Street, Cambridge, MA 02139, USA
| | - Liqun Han
- Seqirus, A CSL Company, 45 Sidney Street, Cambridge, MA 02139, USA
| | | | | |
Collapse
|
49
|
Conformationally selective biophysical assay for influenza vaccine potency determination. Vaccine 2015; 33:5342-5349. [DOI: 10.1016/j.vaccine.2015.08.077] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 08/15/2015] [Accepted: 08/29/2015] [Indexed: 12/19/2022]
|
50
|
Rowlen K. Validation of alternative potency assays for influenza vaccines requires clinical studies. Vaccine 2015; 33:6025-6. [PMID: 26275481 DOI: 10.1016/j.vaccine.2015.07.060] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Revised: 07/02/2015] [Accepted: 07/08/2015] [Indexed: 11/19/2022]
Abstract
Readers of this Special Issue of Vaccine are likely unified by a desire to enhance vaccine efficacy and improve vaccine manufacturing efficiency. For influenza vaccines, challenges to achieving those goals are many, and range from improved surveillance to less cumbersome production platforms and more reliable performance verification. Specifically, demand is growing for an alternative vaccine potency assay. Assuming that a replacement potency assay is found to be promising, one question will be: how will it be judged to be accurate? It is generally agreed that any potential replacement for SRID will have to exhibit good correlation with SRID and yield a value within ± 20% of the SRID determined potency. In my opinion, SRID itself has enough limitations that judging alternatives relative to that particular standard will not ensure that the industry as a whole transitions to an improved method. In fact, it could blind us to an assay that may ultimately provide a better predictive measure of vaccine efficacy (or immunogenicity). There is only one way to verify that measured potency is correlated with, and predictive of, measured immunogenicity - test the relationship in clinical studies.
Collapse
Affiliation(s)
- Kathy Rowlen
- InDevR Inc., 2100 Central Ave., Suite 106, Boulder, CO, United States
| |
Collapse
|